Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study

Hye Jin Kang, Won Seog Kim, Seok Jin Kim, Je Jung Lee, Deok Hwan Yang, Jin Seok Kim, Se Ryeon Lee, Gyeong Won Lee, Hyo Jung Kim, Ho Young Kim, Sung Yong Oh, Hugh Chul Kim, Hyeon Seok Eom, Jooseop Chung, Jinny Park, Cheolwon Suh, Baek Yeol Ryoo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m 2, cyclophosphamide 750 mg/m 2 and vincristine 1.4 mg/m 2 (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.

Original languageEnglish
Pages (from-to)543-551
Number of pages9
JournalAnnals of Hematology
Volume91
Issue number4
DOIs
Publication statusPublished - 2012 Apr

Keywords

  • CVP
  • First-line
  • Immunochemotherapy
  • Marginal zone lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study'. Together they form a unique fingerprint.

  • Cite this

    Kang, H. J., Kim, W. S., Kim, S. J., Lee, J. J., Yang, D. H., Kim, J. S., Lee, S. R., Lee, G. W., Kim, H. J., Kim, H. Y., Oh, S. Y., Kim, H. C., Eom, H. S., Chung, J., Park, J., Suh, C., & Ryoo, B. Y. (2012). Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Annals of Hematology, 91(4), 543-551. https://doi.org/10.1007/s00277-011-1337-6